Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.

Front Immunol · 2021 · PMC8811197 · PMID 35126374

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

Pretreatment with cyclophosphamide had no discernible influence on the time it took to virologic rebound, but a slight trend was observed in improved engraftment in those exposed to cyclophosphamide.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.